right-img

Home Featured News Finance News Banking News

Home | Biogenum Presents Data on Symptom Improvement by BGM-27 Immunotherapy Targeting pTau on Negative Symptoms, Depression, and Social Function in Patients with Alzheimer

Biogenum Presents Data on Symptom Improvement by BGM-27 Immunotherapy Targeting pTau on Negative Symptoms, Depression, and Social Function in Patients with Alzheimer

December 09, 2019
The data will be presented at the Asian Society of Alzheimer Prevention (ASAP) Annual Meeting.

Biogenum (ISIN: KR7013369996), a clinical stage biopharmaceutical company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration, is pleased to announce that it will conduct presentations on BGM-27 immunotherapy targeting pTau at the Asian Society of Alzheim...
Read more at:https://www.1888pressrelease.com/biogenum-presents-data-on-symptom-improvement-by-bgm-27-immu-pr-666952.html

Other News

Biogenum Appoints Kang Tae-suk as Senior Vice President, Head of Regulatory Affairs
Biogenum Funds Expansion of Cognition Study in Running Birth Cohort
Biogenum Presents Periodic Corporate Update
Biogenum Receives $1 Million Grant to Enhance Psychosocial Research for Dementia Care

Site Created by finaceandbankingnewsnow.com